Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAA1 | Q13131 | 10/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.40 |
| ▸ | PRKAA2 | P54646 | 9/20 | 0.39 |
| ▸ | KDR | P35968 | 7/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 2/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | NEK2 | P51955 | 1/20 | 0.36 |
| ▸ | MELK | Q14680 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3579771 | 0.90 | TDP1 (0.48) | PRKAA1CHEK1PRKAA2KDRPDGFRB | |
| SCHEMBL4757647 | 0.89 | PRKAA1 (0.40) | PRKAA1CHEK1PRKAA2KDRPDGFRB | |
| SCHEMBL4757832 | 0.89 | PRKAA1 (0.39) | PRKAA1CHEK1PRKAA2KDRPDGFRB | |
| SCHEMBL4756597 | 0.87 | PRKAA1 (0.38) | PRKAA1CHEK1PRKAA2KDRFLT3 | |
| SCHEMBL3575353 | 0.87 | ACHE (0.40) | PRKAA1CHEK1PRKAA2KDRFLT3 | |
| SCHEMBL3582267 | 0.83 | FLT3 (0.45) | CHEK1KDRFLT3CSF1R | |
| SCHEMBL3573599 | 0.83 | IKBKB (0.43) | KDRFGFR1FLT3 | |
| SCHEMBL3575063 | 0.82 | PLAU (0.41) | NTRK1 | |
| SCHEMBL3572820 | 0.82 | AKT2 (0.38) | PRKAA1CHEK1PRKAA2FLT3CSF1R | |
| SCHEMBL3581709 | 0.81 | AKT2 (0.40) | NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1902025-A1 | KINASE INHIBITORS | Allergan, Inc. (US) | 2008-03-26 | — | — | EP | claimed |
| US-20070032478-A1 | Kinase Inhibitors | ALLERGAN, INC. | 2007-02-08 | — | — | US | claimed |
| WO-2007008895-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2007-01-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032478-A1 | Kinase Inhibitors | ABL1, LCK, ERBB2 | PRKAA1 406/4885CHEK1 161/4885PRKAA2 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.